AASLD

Richmond Pharmacology is excited to join the AASLD Emerging Topic Conference: Unified Frontiers in Liver Disease in Denver, USA, on 05– 09 November 2026.

Bringing together global experts in hepatology, this conference focuses on advancing treatment strategies for steatosis, cholestasis, and other complex liver conditions through cutting-edge science and collaborative innovation.

Representing Richmond Pharmacology

Dr Jörg Taubel, Chief Executive Officer

We look forward to connecting with attendees to discuss Richmond’s expertise in:

• Novel therapies and clinical trial strategies for liver disease

• Biomarker-driven approaches to improve trial efficiency

• Regulatory pathways for emerging hepatology treatments

• Patient-centric recruitment and engagement in liver studies

• Collaboration between academia, industry, and regulators

Connect With Us

If you are attending AASLD Emerging Topic Conference 2026 and would like to explore partnership or development opportunities email us at:

📧 fasteranswers@richmondpharmacology.com

‍